ClinicalTrials.gg

Program

zastaprazan

Also written as “JP-1366 20mg tablet”, “JP-1366 10 mg” and “JP-1366”.

Its studies are mostly in Gastroesophageal Reflux · Ulcer · Peptic Ulcer · Esophagitis · Stomach Ulcer, led by Jeil Pharmaceutical.

Furthest: phase 3, since Jun 28, 202212 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jeil Pharmaceutical123 open or runningphase 3since Jun 28, 2022Dec 18, 2017Aug 2027phase 3 · NCT06439563

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 18, 2017First study: phase 1 study in Anti-Ulcer AgentsFirst studyNCT03383042 · 115 enrolled · Korea, Republic of
  2. Feb 21, 2020Phase 2 study in Gastroesophageal RefluxNCT04282954 · 188 enrolled · Korea, Republic of
  3. Nov 23, 20212 phase 1 studiesNCT05181124, NCT05194046
  4. Jun 28, 20222 phase 3 studiesNCT05448001, NCT05443984
  5. Jan 13, 2023Phase 1 study in HealthyNCT05712681 · 24 enrolled · Korea, Republic of
  6. Apr 3, 2023Phase 1 study in HealthyNCT05814809 · 30 enrolled · Korea, Republic of
  7. May 22, 2024Phase 3 study in Peptic UlcerNCT06439563 · 364 planned · Korea, Republic of
  8. Aug 29, 2025Phase 1 study in HealthyNCT07181538 · 55 enrolled · South Korea
  9. Nov 17, 2025Phase 1 study in Drug Drug Interaction (DDI)NCT07265466 · 96 planned · South Korea
  10. Jul 23, 2026Phase 3 study in Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)NCT07732075 · 384 planned

Ahead

  1. Aug 2027Primary completion: phase 3 study in Peptic UlcerNCT06439563
  2. Oct 30, 2028Primary completion: phase 3 study in Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)NCT07732075

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07732075Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)3Not yet recruitingOct 30, 2028384
NCT07265466Drug Drug Interaction (DDI) · South Korea1RecruitingMar 30, 202696
NCT07181538Healthy · South Korea1CompletedFeb 20, 202555
NCT06439563Peptic Ulcer · Korea, Republic of3RecruitingAug 2027364
NCT05814809Healthy · Korea, Republic of1CompletedOct 9, 202230
NCT05712681Healthy · Korea, Republic of1CompletedMay 4, 202324
NCT05448001Stomach Ulcer · Korea, Republic of3CompletedJul 10, 2024329
NCT05443984Erosive Esophagitis · Korea, Republic of3CompletedJan 5, 2023300
NCT05194046Helicobacter Pylori Associated Gastrointestinal Disease · Korea, Republic of1CompletedJan 16, 202129
NCT05181124Anti-Ulcer Agents · Korea, Republic of1CompletedMar 15, 202188
NCT04282954Gastroesophageal Reflux · Korea, Republic of2CompletedOct 20, 2020188
NCT03383042Anti-Ulcer Agents · Korea, Republic of1CompletedNov 23, 2018115

How it is read

Names in the registry

  • “JP-1366 20mg tablet”, 3 entries
  • “JP-1366 10 mg”, 2 entries
  • “JP-1366”, 2 entries
  • “JP-1366 20mg”, 2 entries
  • “JP-1366 and clopidogrel”, 1 entry

Codes read as this program: JP1366.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.